Deterministic transfection drives efficient nonviral reprogramming and uncovers reprogramming barriers.

ABSTRACT: Safety concerns and/or the stochastic nature of current transduction approaches have hampered nuclear reprogramming's clinical translation. We report a novel non-viral nanotechnology-based platform permitting deterministic large-scale transfection with single-cell resolution. The superior capabilities of our technology are demonstrated by modification of the well-established direct neuronal reprogramming paradigm using overexpression of the transcription factors Brn2, Ascl1, and Myt1l (BAM). Reprogramming efficiencies were comparable to viral methodologies (up to ~9-12%) without the constraints of capsid size and with the ability to control plasmid dosage, in addition to showing superior performance relative to existing non-viral methods. Furthermore, increased neuronal complexity could be

SUBMITTER: Gallego-Perez D 

PROVIDER: S-EPMC5161095 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature